Increased frequency of genetic thrombophilia in women with complications of pregnancy

New England Journal of Medicine

Volumn 340, Issue 1, 1999, Pages 9-13

  Kupferminc, Michael J ^a,b   Eldor, Amiram ^a   Steinman, Nitzan ^a   Many, Ariel ^a   Bar Am, Amiram ^a   Jaffa, Ariel ^a   Fait, Gideon ^a   Lessing, Joseph B ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b LIS MATERNITY HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CARDIOLIPIN ANTIBODY; PROTEIN C; PROTEIN S;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; THROMBOPHILIA;

ABRUPTIO PLACENTAE; ADULT; AMINO ACID SUBSTITUTION; ANTIBODIES, ANTICARDIOLIPIN; ANTITHROMBIN III DEFICIENCY; CASE-CONTROL STUDIES; FACTOR V; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; HUMANS; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP); MUTATION; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA;

EID: 0033531184     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901073400102     Document Type: Article

References (33)

1. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4.
2. Salafia CM, Pezzullo JC, Lopez-Zeno JA, Simmens S, Minior VK, Vintzileos AM. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995;173:1097-105.
3. Shanklin DR, Sibai BM. Ultrastructural aspects of preeclampsia. I. Placental bed and uterine boundary vessels. Am J Obstet Gynecol 1989;161: 735-41.
4. Khong TY, Pearce JM, Robertson WB. Acute atherosis in preeclampsia: maternal determinants and fetal outcome in the presence of the lesion. Am J Obstet Gynecol 1987;157:360-3.
5. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am J Obstet Gynecol 1995;173:1049-57.
6. Creasy RK, Resnik R, eds. Maternal-fetal medicine: principles and practice. 3rd ed. Philadelphia: W.B. Saunders, 1994:609-10.
7. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss: a case-control study. N Engl J Med 1991;325:1063-6.
8. Dahlback B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994;24:139-51.
9. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
10. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
11. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
12. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
14. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
15. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7.
16. Hypertension in pregnancy. Technical bulletin no. 219. Washington, D.C.: American College of Obstetricians and Gynecologists, January 1996.
17. Brenner WE, Edelman DA, Hendricks CH. A standard of fetal growth for the United States of America. Am J Obstet Gynecol 1976;126:555-64.
18. Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn U. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood 1996;88:877-80.
19. Brenner B, Mandel H, Lanir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97:551-4.
20. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
21. Seligsohn U, Zivelin A. Thrombophilia as a multigcnic disorder. Thromb Haemost 1997;78:297-301.
22. Dekker GA, de Vries JI, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
23. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-5.
24. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997;77:1052-4.
25. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997;176:457-60.
26. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-6.
27. 506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemost 1998;79:69-73.
28. Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-45.
29. Molloy AM, Daly S, Mills JL, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997;349:1591-3.
30. Sohda S, Arinami T, Hamada HM, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997;34:525-6.
31. Goddijn-Wessel TA, Wouters MG, van de Molen EF, et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996;66:23-9.
32. de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997;104:1248-54.
33. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998;338:701-5.